Comparison · NCT00514904-sae
Nimenrix Group vs Mencevax ACWY Group: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nimenrix Group vs Mencevax ACWY Group: serious adverse events. Trial comparisons, record NCT00514904-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00514904-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0133 | 0.0081 | 0.0219 | wilson | |
| Risk in group 2 | 0.0186 | 0.00905 | 0.0379 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00528 | -0.0253 | 0.00755 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.716 | 0.294 | 1.74 | log | |
| Odds ratio, group 1 over group 2 | 0.712 | 0.288 | 1.76 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Nimenrix Group than on Mencevax ACWY Group | 189 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nimenrix Group | Subjects received 1 dose of Nimenrix vaccine at Month 0. Nimenrix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm. | 15 | 1,125 | EG000 |
| Group 2 | Mencevax ACWY Group | Subjects received 1 dose of Mencevax ACWY vaccine at Month 0. Mencevax ACWY vaccine was administered subcutaneously into the upper region of the non-dominant arm. | 7 | 376 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Serious adverse events: from Day 0 up to 6 months after vaccination. Solicited symptoms: during the 4-day (Day 0-Day 3) follow-up period after vaccination.
Source ClinicalTrials.gov
Trial
- Title
- Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects
- NCT number
- NCT00514904
- Phases
- PHASE3
- Conditions
- Infections, Meningococcal, Meningococcal Vaccines
- Interventions
- Nimenrix, Mencevax
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2017-10-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00514904?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00514904-sae